Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can video therapy and blood markers help predict and prevent suicide?

NCT ID NCT07857291

Symptom relief Sponsor: Hyung Keun Park Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 05, 2026 · Last updated Oct 06, 2026 · Updated 1 time

Summary

Researchers are testing whether brief cognitive behavioral therapy delivered by video call can reduce suicide attempts in adults with mood disorders who are at high risk. The study also compares blood levels of inflammatory proteins among high-risk patients, low-risk patients, and healthy volunteers to see if these markers can identify suicide risk. High-risk participants receive either the video therapy plus usual care or usual care alone, and researchers track suicide attempts and symptom changes over several months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Videoconference-based brief cognitive behavioral therapy
What this could lead to
If it works, this could offer a remote therapy option that helps people with mood disorders avoid suicide attempts. It could also point to inflammation markers that help doctors spot who is at highest risk.
What could go wrong
This is a single study, and therapy delivered by video may not work as well as in-person care for everyone. The inflammation markers may not reliably predict suicide risk, and the results may not apply to people outside the study groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 64 years. * For patient groups: diagnosis of a depressive disorder or bipolar and related disorder with a current major depressive episode according to DSM-5 criteria, as assessed using the Mini International Neuropsychiatric Interview (MINI). * For the high-suicide-risk group: either a suicide attempt within the past month or a Beck Scale for Suicide Ideation (SSI) score of ≥15. * For healthy controls: no lifetime history of any DSM-5 psychiatric disorder, as assessed using the MINI. Exclusion Criteria: * Presence of psychotic symptoms or a current substance use disorder. * Diagnosis of an inflammatory or autoimmune disease. * Current use of corticosteroids or immunosuppressive medications. * Current pregnancy or breastfeeding. * Diagnosis of cancer within the past 5 years. * Physical injury or infectious illness within the past month. * Night-shift work within the past 2 months. * Receipt of psychotherapy or psychological treatment within the past 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behavior bipolar disorder major depressive disorder mood disorder Suicidal Ideation Suicide, Attempted

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive behavior therapy Mood disorders Suicidal ideation and behavior Suicide attempt

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.